Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats

Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats is organized by Society for Translational Oncology (STO).

Released: 1/13/2021
Expires: 12/14/2022 

Learning Objectives:
• Describe the optimal anticoagulant treatment of patients with cancer-associated venous thromboembolism (VTE) and the clinical data supporting these strategies.
• Incorporate data from DOAC and LMWH clinical trials into clinical decision-making for treatment of cancer patients with venous thromboembolism.

Additional details will be posted as soon as information is available.